1,9-Dimethylhypoxanthin | 20535-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,9-Dimethylhypoxanthin
• 英文别名: 1,9-Dimethylhypoxanthine；1,9-dimethylpurin-6-one
• CAS: 20535-82-4
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: KIHZGMYZXVZBRG-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  415.1±37.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  50.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  次黄嘌呤 、 N,N-二甲基甲酰胺 生成 1,9-Dimethylhypoxanthin
  参考文献：
  名称：

  STANOVNIK, B.;MIRTIC, T.;KOREN, B.;TISLER, M.;BELCIC, B., VESTN. SLOV. KEM. DRUST., 1982, 29, N 4, 331-343

  摘要：

  DOI：

文献信息

• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：Alios BioPharma, Inc.

  公开号：US20130165400A1

  公开（公告）日：2013-06-27

  Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

  本文披露了核苷、核苷酸及其类似物，包括一个或多个核苷、核苷酸及其类似物的药物组合物，以及它们的合成方法。本文还披露了使用核苷、核苷酸和其类似物来改善和/或治疗疾病和/或病况的方法，包括使用核苷、核苷酸和其类似物来治疗副粘病毒和/或正粘病毒感染的方法。
• CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES)
  申请人：Pfizer Inc.

  公开号：EP3765474B1

  公开（公告）日：2022-06-15
• Protected monomers
  申请人：Manoharan Muthiah

  公开号：US20070179100A1

  公开（公告）日：2007-08-02

  This invention relates to protected monomers for the synthesis of iRNA agents.
• Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：US20210344045A1

  公开（公告）日：2021-11-04

  A nonaqueous electrolyte solution is provided comprising a nonaqueous solvent containing acetonitrile at 5 vol % to 95 vol %; a lithium salt; and one or more compounds having a structure satisfying the following conditions 1 to 5: 1. being a condensation polycyclic heterocyclic ring compound, 2. containing a pyrimidine backbone in the condensation polycyclic heterocyclic ring, 3. containing 3 or more nitrogen atoms in the condensation polycyclic heterocyclic ring, 4. containing 5 or more sp2 carbons in the condensation polycyclic heterocyclic ring, and 5. having no hydrogen atoms bonded to the nitrogen atoms in the condensation polycyclic heterocyclic ring.
• [EN] ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'ÉCTONUCLÉOTIDASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALITHERA BIOSCIENCES INC

  公开号：WO2018049145A1

  公开（公告）日：2018-03-15

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

表征谱图